1. Home
  2. CTRM vs ABP Comparison

CTRM vs ABP Comparison

Compare CTRM & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castor Maritime Inc.

CTRM

Castor Maritime Inc.

HOLD

Current Price

$1.97

Market Cap

21.2M

ML Signal

HOLD

ABP

Abpro Holdings Inc Common Stock

BUY

Current Price

$6.80

Market Cap

18.8M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
CTRM
ABP
Founded
2016
2004
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.2M
18.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CTRM
ABP
Price
$1.97
$6.80
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
37.7K
207.2K
Earning Date
11-07-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$67,859,415.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
50.00
52 Week Low
$1.84
$4.55
52 Week High
$3.64
$153.90

Technical Indicators

Market Signals
Indicator
CTRM
ABP
Relative Strength Index (RSI) 48.36 88.76
Support Level $1.85 $5.34
Resistance Level $1.99 $7.02
Average True Range (ATR) 0.07 0.49
MACD 0.01 -0.06
Stochastic Oscillator 48.83 73.00

Price Performance

Historical Comparison
CTRM
ABP

About CTRM Castor Maritime Inc.

Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.

About ABP Abpro Holdings Inc Common Stock

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.

Share on Social Networks: